R
Rafal Tarnawski
Researcher at Curie Institute
Publications - 86
Citations - 2651
Rafal Tarnawski is an academic researcher from Curie Institute. The author has contributed to research in topics: Radiation therapy & Medicine. The author has an hindex of 21, co-authored 75 publications receiving 2297 citations.
Papers
More filters
Journal ArticleDOI
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp,Roger Stupp,Monika E. Hegi,Thierry Gorlia,Sara Erridge,James Perry,Yong-Kil Hong,Kenneth Aldape,Benoit Lhermitte,Torsten Pietsch,Danica Grujicic,Joachim P. Steinbach,Wolfgang Wick,Rafal Tarnawski,Do-Hyun Nam,Peter Hau,Astrid Weyerbrock,Martin J B Taphoorn,Chiung-Chyi Shen,Nalini Rao,László Thurzó,Ulrich Herrlinger,Tejpal Gupta,Rolf-Dieter Kortmann,Krystyna Adamska,Catherine McBain,Alba A. Brandes,Joerg C. Tonn,Oliver Schnell,Thomas Wiegel,Chae-Yong Kim,Louis B. Nabors,David A. Reardon,Martin J. van den Bent,Christine Hicking,Andriy Markivskyy,Martin Picard,Michael Weller +37 more
TL;DR: This multicentre, open-label, phase 3 study investigated the efficacy of cilengitide in patients from 146 study sites in 25 countries and found none of the predefined clinical subgroups showed a benefit.
Journal ArticleDOI
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
L. Burt Nabors,Karen Fink,Tom Mikkelsen,Danica Grujicic,Rafal Tarnawski,Do-Hyun Nam,Maria Mazurkiewicz,Michael Salacz,Lynn S. Ashby,Vittorina Zagonel,Roberta Depenni,James Perry,Christine Hicking,Martin Picard,Monika E. Hegi,Benoit Lhermitte,David A. Reardon +16 more
TL;DR: Standard and intensive cilengitide dose regimens were well tolerated in combination with TMZ/RT→TMZ and a limited sample size did not allow firm conclusions regarding clinical efficacy in this exploratory phase II study.
Journal ArticleDOI
Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients.
Rafał Suwiński,Anna Sowa,Tomasz Rutkowski,Jerzy Wydmański,Rafal Tarnawski,Bogusław Maciejewski +5 more
TL;DR: It is assumed that a highly significant adverse influence of radiation treatment gaps on the rate of tumor control is consistent with rapid repopulation of cancer clonogenes during PRT, and that the duration of time interval surgery-PRT appeared, by contrast, only borderline significant for RFS.
Journal ArticleDOI
Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity.
Krzysztof Składowski,Bogusław Maciejewski,M. Goleń,Bolesław Pilecki,W. Przeorek,Rafal Tarnawski +5 more
TL;DR: The gain in tumour control is likely the effect of shortening of overall treatment time by 14 days and regular continuous dose delivery during the whole course of radiation therapy including weekends.
Journal ArticleDOI
Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2)
Loren K. Mell,Igor Sirák,Lichun Wei,Rafal Tarnawski,Umesh Mahantshetty,Catheryn M. Yashar,Michael T. McHale,Ronghui Xu,Gordon Honerkamp-Smith,Ruben Carmona,M.E. Wright,Casey W. Williamson,Linda Kašaová,Nan Li,Stephen Kry,Jeff M. Michalski,Walter Bosch,William Straube,Julie K. Schwarz,Jessica Lowenstein,Steve B. Jiang,Cheryl C. Saenz,S.C. Plaxe,John P. Einck,Chonlakiet Khorprasert,Paul Koonings,Terry A. Harrison,Mei Shi,Arno J. Mundt +28 more
TL;DR: Positron emission tomography-based image-guided IMRT (IG-IMRT) reduces acute hematologic and GI toxicity compared with standard treatment, with promising therapeutic outcomes.